Literature DB >> 29608150

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity.

Kelly Sheehan1, Sandeep Sheth2, Debashree Mukherjea1, Leonard P Rybak3, Vickram Ramkumar4.   

Abstract

The systemic administration of protective agents to treat drug-induced ototoxicity is limited by the possibility that these protective agents could interfere with the chemotherapeutic efficacy of the primary drugs. This is especially true for the drug cisplatin, whose anticancer actions are attenuated by antioxidants which provide adequate protection against hearing loss. Other current or potential otoprotective agents could pose a similar problem, if administered systemically. The application of various biologicals or protective agents directly to the cochlea would allow for high levels of these agents locally with limited systemic side effects. In this report, we demonstrate a trans-tympanic method of delivery of various drugs or biological reagents to the cochlea, which should enhance basic science research on the cochlea and provide a simple way of directing the use of otoprotective agents in the clinics. This report details a method of trans-tympanic drug delivery and provides examples of how this technique has been used successfully in experimental animals to treat cisplatin ototoxicity.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29608150      PMCID: PMC5931769          DOI: 10.3791/56564

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  20 in total

Review 1.  Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy?

Authors:  Brian D Lawenda; Kara M Kelly; Elena J Ladas; Stephen M Sagar; Andrew Vickers; Jeffrey B Blumberg
Journal:  J Natl Cancer Inst       Date:  2008-05-27       Impact factor: 13.506

2.  Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study.

Authors:  Maryam Fouladi; Susan M Blaney; Tina Young Poussaint; Burgess B Freeman; Roger McLendon; Christine Fuller; Adekunle M Adesina; Michael L Hancock; Mary K Danks; Clinton Stewart; James M Boyett; Amar Gajjar
Journal:  Cancer       Date:  2006-11-01       Impact factor: 6.860

3.  Subclasses of external adenosine receptors.

Authors:  C Londos; D M Cooper; J Wolff
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

4.  Effect of protective agents against cisplatin ototoxicity.

Authors:  L P Rybak; K Husain; C Morris; C Whitworth; S Somani
Journal:  Am J Otol       Date:  2000-07

5.  NOX3 NADPH oxidase couples transient receptor potential vanilloid 1 to signal transducer and activator of transcription 1-mediated inflammation and hearing loss.

Authors:  Debashree Mukherjea; Sarvesh Jajoo; Kelly Sheehan; Tejbeer Kaur; Sandeep Sheth; Jennifer Bunch; Christopher Perro; Leonard P Rybak; Vickram Ramkumar
Journal:  Antioxid Redox Signal       Date:  2010-12-07       Impact factor: 8.401

6.  Mechanisms of apoptosis induced by cisplatin in marginal cells in mouse stria vascularis.

Authors:  Ji Eun Lee; Takayuki Nakagawa; Tomoko Kita; Tae Soo Kim; Fukuichiro Iguchi; Tsuyoshi Endo; Atsushi Shiga; Sang Heun Lee; Juichi Ito
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  2004       Impact factor: 1.538

Review 7.  Comparative adverse effect profiles of platinum drugs.

Authors:  M J McKeage
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

8.  Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.

Authors:  Andrea Ardizzoni; Luca Boni; Marcello Tiseo; Frank V Fossella; Joan H Schiller; Marianne Paesmans; Davorin Radosavljevic; Adriano Paccagnella; Petr Zatloukal; Paola Mazzanti; Donald Bisset; Rafael Rosell
Journal:  J Natl Cancer Inst       Date:  2007-06-06       Impact factor: 13.506

Review 9.  Cisplatin and platinum drugs at the molecular level. (Review).

Authors:  Teni Boulikas; Maria Vougiouka
Journal:  Oncol Rep       Date:  2003 Nov-Dec       Impact factor: 3.906

10.  Mouse Auditory Brainstem Response Testing.

Authors:  Omar Akil; A E Oursler; Kevin Fan; Lawrence R Lustig
Journal:  Bio Protoc       Date:  2016-03-20
View more
  6 in total

1.  Targeting Inflammatory Processes Mediated by TRPVI and TNF-α for Treating Noise-Induced Hearing Loss.

Authors:  Asmita Dhukhwa; Puspanjali Bhatta; Sandeep Sheth; Krishi Korrapati; Coral Tieu; Chaitanya Mamillapalli; Vickram Ramkumar; Debashree Mukherjea
Journal:  Front Cell Neurosci       Date:  2019-10-03       Impact factor: 5.505

Review 2.  Local Drug Delivery for Prevention of Hearing Loss.

Authors:  Leonard P Rybak; Asmita Dhukhwa; Debashree Mukherjea; Vickram Ramkumar
Journal:  Front Cell Neurosci       Date:  2019-07-09       Impact factor: 5.505

3.  Oral Administration of Caffeine Exacerbates Cisplatin-Induced Hearing Loss.

Authors:  Sandeep Sheth; Kelly Sheehan; Asmita Dhukhwa; Raheem F H Al Aameri; Chaitanya Mamillapalli; Debashree Mukherjea; Leonard P Rybak; Vickram Ramkumar
Journal:  Sci Rep       Date:  2019-07-02       Impact factor: 4.379

4.  Regulator of G protein signaling 17 represents a novel target for treating cisplatin induced hearing loss.

Authors:  Asmita Dhukhwa; Raheem F H Al Aameri; Sandeep Sheth; Debashree Mukherjea; Leonard Rybak; Vickram Ramkumar
Journal:  Sci Rep       Date:  2021-04-14       Impact factor: 4.379

Review 5.  Strategies to reduce the risk of platinum containing antineoplastic drug-induced ototoxicity.

Authors:  Debashree Mukherjea; Asmita Dhukhwa; Amit Sapra; Priyanka Bhandari; Katlyn Woolford; Jacob Franke; Vickram Ramkumar; Leonard Rybak
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-09-29       Impact factor: 4.481

6.  The Endocannabinoid/Cannabinoid Receptor 2 System Protects Against Cisplatin-Induced Hearing Loss.

Authors:  Sumana Ghosh; Sandeep Sheth; Kelly Sheehan; Debashree Mukherjea; Asmita Dhukhwa; Vikrant Borse; Leonard P Rybak; Vickram Ramkumar
Journal:  Front Cell Neurosci       Date:  2018-08-21       Impact factor: 5.505

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.